SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML

An RNAi-based system for loss-of-function analysis identifies Raf1 as a crucial mediator of BCR-ABL-driven leukemogenesis

(2011) C. Albers et al.   BLOOD

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

SRC hits the mark

(2011) Darren J. Burgess   NATURE REVIEWS DRUG DISCOVERY

Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice

(2010) S. P. Gorantla et al.   BLOOD

FLT3 as a therapeutic target in AML: still challenging after all these years

(2010) T. Kindler et al.   BLOOD

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

(2010) Thomas Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome

(2009) S. Kayser et al.   BLOOD

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality

(2009) D. Schmidt-Arras et al.   BLOOD

Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3

(2009) Kristina Masson et al.   CELLULAR SIGNALLING

Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation

(2009) Elena Razumovskaya et al.   EXPERIMENTAL HEMATOLOGY

Dissection of PIM serine/threonine kinases in FLT3-ITD–induced leukemogenesis reveals PIM1 as regulator of CXCL12–CXCR4-mediated homing and migration

(2009) Rebekka Grundler et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes

(2009) Chunaram Choudhary et al.   MOLECULAR CELL

Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib

(2009) Bella S. Guerrouahen et al.   PEDIATRIC BLOOD & CANCER

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor

(2008) F. Breitenbuecher et al.   BLOOD

Transformation by Oncogenic Mutants and Ligand-Dependent Activation of FLT3 Wild-type Requires the Tyrosine Residues 589 and 591

(2008) S. Vempati et al.   CLINICAL CANCER RESEARCH

Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors

(2008) H Konig et al.   LEUKEMIA

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE